PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Ryan J. Duchatel(Hunter Medical Research Institute), David M. Ashley(Unknown), Izac J. Findlay(Hunter Medical Research Institute), Susan Hua(University of Newcastle Australia), Mika L. Persson(Hunter Medical Research Institute), Ron Firestein(Unknown), Paul Daniel(Brigham and Women's Hospital), Sandra Laternser(University Children's Hospital Zurich), Maria Tsoli(Cancer Institute of New South Wales), Murray J. Cairns(Hunter Medical Research Institute), Charles E. de Bock(Cancer Institute of New South Wales), Dilana E. Staudt(Hunter Medical Research Institute), Elizabeth E. Manning(University of Pittsburgh), Jordan R. Hansford, Abdul Mannan(Jeju National University), Claire Sun(Hudson Institute of Medical Research), Yolanda Colino‐Sanguino(UNSW Sydney), Nicholas A. Vitanza(Seattle Children's Hospital), James R. Whittle(Walter and Eliza Hall Institute of Medical Research), Emily Hocke(Duke University), Frank Alvaro(ANZCHOG), Fátima Valdés‐Mora(Cancer Institute of New South Wales), Vaibhav Jain(Duke University), David S. Ziegler(Cancer Institute of New South Wales), Eric H. Raabe(Johns Hopkins University), Santosh Valvi(The Kids Research Institute Australia), Christopher L. Tinkle(St. Jude Children's Research Hospital), M. Fairuz B. Jamaluddin(University of Newcastle Australia), Alicia M. Douglas(Hunter Medical Research Institute), Holly P. McEwen(Hunter Medical Research Institute), Tyrone S. Beitaki(Hunter Medical Research Institute), Michael Aksu(Duke University), Timothy N. Phoenix(University of Cincinnati), Brett Nixon(Hunter Medical Research Institute), David D. Eisenstat(Royal Children's Hospital), Zacary P. Germon(Hunter Medical Research Institute), Nicole M. Verrills(Hunter Medical Research Institute), Padraic S. Kearney(Hunter Medical Research Institute), Esther Hulleman(Amsterdam UMC Location VUmc), Helen Wheeler(The University of Sydney), Heather C. Murray(Hunter Medical Research Institute), David A. Skerrett‐Byrne(Helmholtz Zentrum München), Sarah Parackal(Monash University), Christopher V. Dayas(Hunter Medical Research Institute), Ricardo E. Vilain(Hunter Medical Research Institute), Dylan Kiltschewskij(Hunter Medical Research Institute), Bryce Thomas(Hunter Medical Research Institute), Evangeline R. Jackson(Hunter Medical Research Institute), Sabine Mueller, Carl Koschmann(University of Michigan)
Cited by 44
Related Papers
Advances and Challenges of Liposome Assisted Drug Delivery
|Frontiers in Pharmacology|2015|2.5k
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795